Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNa Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of asthma, dermatomyositis, and all food allergies; and kinoid vaccine that simultaneously targets IL-4 and IL-13 allergies. The company was founded in 1993 and is based in Suresnes, France.…
Ajustement de la dilution de Neovacs SA – MUN:0LW1
Neovacs (EPA: ALNEV) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.0459 EUR on 20 November 2026, down 100.0% over 52 weeks. Its 52-week range is 0.0002 EUR to 267.00 EUR: the price is 100.0% below the high and 22850.0% above the low.
Its market capitalisation is 7.34K EUR.
Neovacs reports return on equity of -182.2% and revenue up 250.8% year over year.
Its debt exceeds its cash by 695.47K EUR, a debt-to-equity ratio of 0.01. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.
No upcoming events tracked.